Phase I, Open Label Dose Escalation and Dose Expansion Study to Evaluate the Safety, Expansion, Persistence, and Clinical Activity of a Single Dose of UCART123 (Allogeneic Engineered T Cells Expressing Anti-CD123 Chimeric Antigen Receptor), Administered in Patients With Relapsed/Refractory Acute Myeloid Leukemia, and Patients With Newly Diagnosed High-risk Acute Myeloid Leukemia

Trial Profile

Phase I, Open Label Dose Escalation and Dose Expansion Study to Evaluate the Safety, Expansion, Persistence, and Clinical Activity of a Single Dose of UCART123 (Allogeneic Engineered T Cells Expressing Anti-CD123 Chimeric Antigen Receptor), Administered in Patients With Relapsed/Refractory Acute Myeloid Leukemia, and Patients With Newly Diagnosed High-risk Acute Myeloid Leukemia

Recruiting
Phase of Trial: Phase I

Latest Information Update: 03 Jul 2017

At a glance

  • Drugs UCART 123 (Primary)
  • Indications Acute myeloid leukaemia
  • Focus Adverse reactions; First in man
  • Sponsors Cellectis
  • Most Recent Events

    • 27 Jun 2017 According to a Cellectis media release, Dr. Monica Guzman, an associate professor of pharmacology in medicine at Weill Cornell Medicine, is a co-principal investigator of the study.
    • 27 Jun 2017 According to a Cellectis media release, first patient has been enrolled and dosed.
    • 15 Jun 2017 Status changed from planning to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top